Approval of funding for Juno Pemetrexed for the treatment of mesothelioma and NSCLC in NZ

18 August 2017

New Zealand’s Pharmaceutical Management Agency PHARMAC today announced the approval of a proposal to fund pemetrexed for the treatment of mesothelioma and non-small cell lung cancer (NSCLC) in conjunction with the awarding of pemetrexed tender bids as part of PHARMAC’s 2015/16 annual Invitation to Tender.

In summary, the effect of the decision is that:

Pemetrexed will be listed on the Pharmaceutical Schedule from November 1, 2017 for the treatment of patients with mesothelioma and locally advanced or metastatic non-squamous NSCLC who meet certain clinical criteria.
Juno Pharmaceutical NZ Limited’s brand of pemetrexed, Juno Pemetrexed, will have Hospital Supply Status within DHB hospitals, with a Discretionary Variance (DV) Limit of 1%, from January 1, 2018 until June 30, 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK